CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...